Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
[177Lu]Lu-NeoB + temozolomide
- Development stage
- Unknown
- Lead developer
- Novartis
- Modality
- Small Molecules, Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics
- Administration
- Intravenous, Oral
01
Overview
**[177Lu]Lu-NeoB + temozolomide** is a combination investigational therapy comprising a radiolabeled GRPR-targeting peptide ([177Lu]Lu-NeoB) and the alkylating chemotherapy agent temozolomide. [177Lu]Lu-NeoB is a radiopharmaceutical that binds to gastrin-releasing peptide receptor (GRPR), which is expressed in various cancers, and delivers cytotoxic beta radiation via the lutetium-177 radionuclide, causing DNA damage and cancer cell death. Temozolomide is an oral alkylating agent that adds methyl groups to DNA, leading to apoptosis in rapidly dividing tumor cells. This combination is under investigation alongside radiotherapy for the treatment of newly diagnosed glioblastoma, aiming to improve tumor control by uniting targeted radioligand therapy with standard chemoradiation[1][2][4]. The combination is also being tested in clinical trials to determine its safety, efficacy, and optimal dosing.
- Other names
- lutetium-177 NeoBlutetium177 NeoBlutetium 177 NeoBNeoBOMB1NeoBOMB-1NeoBOMB 1TMZ[177Lu]Lu-NeoB + TMZ
02
Targets
DNAGRPR (Gastrin-releasing peptide receptor)
Beyond the preview
Go deeper on [177Lu]Lu-NeoB + temozolomide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on [177Lu]Lu-NeoB + temozolomide.